Cargando…

Pretreatment (18)F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

OBJECTIVE: Intra-tumoral heterogeneity of (18)F‐fluorodeoxyglucose ((18)F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positive b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Guang, You, Shuhui, Xie, Yizhao, Gu, Bingxin, Liu, Cheng, Hu, Xichun, Song, Shaoli, wang, Biyun, Yang, Zhongyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510219/ https://www.ncbi.nlm.nih.gov/pubmed/37726862 http://dx.doi.org/10.1186/s40644-023-00608-0

Ejemplares similares

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Prediction of Pretreatment 18F-FDG-PET/CT Parameters on the Outcome of First-Line Therapy in Patients with Metastatic Breast Cancer
por: Li, Yi, et al.
Publicado: (2021)

Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients
por: Xie, Yizhao, et al.
Publicado: (2022)

Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by (18)F-FES PET
por: Xie, Yizhao, et al.
Publicado: (2022)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation
por: Nami, Babak, et al.
Publicado: (2019)

Correction: Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

Pruritus Related to Trastuzumab and Pertuzumab in HER2+ Breast Cancer Patients
por: Gu, Stephanie, et al.
Publicado: (2023)

Prognostic Value of Tumor Heterogeneity on 18F-FDG PET/CT in HR+HER2− Metastatic Breast Cancer Patients receiving 500 mg Fulvestrant: a retrospective study
por: Zhao, Yannan, et al.
Publicado: (2018)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain †
por: Cruz, Victor L., et al.
Publicado: (2023)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+) breast cancer in the adaptively randomized I-SPY2 trial
por: Clark, Amy S., et al.
Publicado: (2021)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
por: Nami, Babak, et al.
Publicado: (2018)

A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2
por: Lua, Wai-Heng, et al.
Publicado: (2015)

Establishment and validation of a nomogram with intratumoral heterogeneity derived from (18)F-FDG PET/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma
por: Gu, Bingxin, et al.
Publicado: (2020)

Heterogeneity of targeted lung lesion predicts platinum-based first-line therapy outcomes and overall survival for metastatic triple-negative breast cancer patients with lung metastasis: a “PET biopsy” method
por: Xie, Yizhao, et al.
Publicado: (2019)

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer
por: Yu, Anthony F., et al.
Publicado: (2016)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer
por: Liu, Yan-cui, et al.
Publicado: (2019)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression
por: Aboudaram, Amélie, et al.
Publicado: (2021)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
por: Hall, Benjamin James, et al.
Publicado: (2022)

Pretreatment (18) F-FDG uptake heterogeneity can predict survival in patients with locally advanced nasopharyngeal carcinoma——a retrospective study
por: Yang, Zhongyi, et al.
Publicado: (2015)

Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab
por: Mortimer, Joanne E., et al.
Publicado: (2019)

Effect of VH–VL Families in Pertuzumab and Trastuzumab Recombinant Production, Her2 and FcγIIA Binding
por: Ling, Wei-Li, et al.
Publicado: (2018)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Favourable outcome of patients with breast cancer brain metastases treated with dual HER2 blockade of trastuzumab and pertuzumab
por: Bergen, Elisabeth Sophie, et al.
Publicado: (2021)

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials
por: Liu, Xiaoyun, et al.
Publicado: (2022)

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
por: de Azambuja, E., et al.
Publicado: (2023)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2020)

Acquired resistance to trastuzumab/pertuzumab or to T‐DM1 in vivo can be overcome by HER2 kinase inhibition with TAS0728
por: Irie, Hiroki, et al.
Publicado: (2020)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
por: Jagosky, Megan, et al.
Publicado: (2021)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
por: Ferraro, Emanuela, et al.
Publicado: (2022)

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
por: Xiao, Yi, et al.
Publicado: (2022)

Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
por: Ma, Xiangmin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_31joamhmu48pp9755sh4n8thpo